Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: A pharmacokinetic study in a Mexican population

Clinical Drug Investigation

Volumn 26, Issue 6, 2006, Pages 323-328

  Marcelín Jiménez, Gabriel ^a   Ángeles, Alionka P ^a   Martínez Rossier, Luis ^a   Fernández, S Adolfo ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CIPROFLOXACIN PLUS PHENAZOPYRIDINE; NOVOQUIN; UNCLASSIFIED DRUG; VODELAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MEAN RESIDENCE TIME; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

ADMINISTRATION, ORAL; ADULT; ANESTHETICS, LOCAL; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MEXICO; NAUSEA; PHENAZOPYRIDINE; TABLETS; TIME FACTORS;

EID: 33745056804     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626060-00003     Document Type: Article

References (16)

1. Distribución de los casos nuevos de enfermedades en los Estados Unidos Mexicanos. Dirección General de Epidemiología, SSA. Anuario 2004 [online]. Available from URL: http://www.dgepi.salud.gob.mx [Accessed 2005 Jul]
2. Mehnert-Kay SA. Diagnosis and management of uncomplicated urinary infections. Am Fam Physician 2005; 72: 451-546
3. Mascellino MT, Farinelli S, Legri F, et al. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical Gram-positive and Gram-negative isolates. Drug Exp Clin Res 1998; 24: 139-51
4. Goldstein EJC, Citron DM, Hunt GS, et al. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates. Antimicrob Agents Chemother 1997; 41: 1193-5
5. Grude N, Tveten Y, Jenkins A, et al. Uncomplicated urinary tract infections: bacterial findings and efficacy of empirical antibacterial treatment. Scand J Prim Health Care 2005; 2: 115-9
6. Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother 1983; 23: 559-64
7. Sörgel F, Jaehde U, Naber K, et al. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet 1989; 16 Suppl. 1: 5-24
8. Mandel GJ, Petri Jr WA. Sulfonamides, trimethoprimsulfamethoxazole, quinolones and agents for urinary tract infections. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's The pharmacological basis of therapeutics, 9th edition. New York: McGraw Hill International, 1996: 1057-72
9. Gaines KK. Phenazopyridine hydrochloride: the use and abuse of an old standby for UTI. Urol Nurs 2004; 24: 207-9
10. Samanidou VF, Demetriou CE, Papadoyannis IN. Direct determination of four fluoroquinolones enoxacin, norfloxacin, ofloxacin and ciprofloxacin in pharmaceuticals and blood serum by HPLC. Anal Bioanal Chem 2003; 375: 623-9
11. Weber A, Chaffin D, Smith A, et al. Quantitation of ciprofloxacin in body fluids by HPLC. Antimicrob Agents Chemother 1985; 27: 531-4
12. Morton SJ, Shull VH, Dick JD. Determination of norfloxacin and ciprofloxacin concentrations in serum and urine by HPLC. Antimicrob Agents Chemother 1986; 30: 325-7
13. Du Preez JL, Botha SA, Lôtter AP. HPLC determination of phenazopyridine HCl, tetracycline HCl and sulfametizole in combination. J Chromatogr 1985; 333: 249-52
14. Lin CE, Deng Jr Y, Liao WS, et al. Electrophoretic behaviour and pKa determination of quinolones with a piperazinyl substituent by capillary zone electrophoresis. J Chromatogr A 2004; 1051 (1-2): 283-90
15. Gaspari R, Bosker G. Urinary tract infections: risk stratification, clinical evaluation and evidence-based antibiotic therapy. Primary Care Consensus Reports. American Health Consultants; 2003 Update
16. Naber KG, Landen H. Rapid resolution of symptoms with ciprofloxacin therapy in 3859 hospitalized patients with urinary tract infections. Int J Antimicrob Agents 2004; 23 Suppl. 1: S35-40